Find a Clinical Trial by Phase

Adult Cancers
Childhood Cancers
Doctor
Drug
Phase

New studies open frequently, please check back for updates

The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.

Back to Phases

Phase: III

70 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.

Doctor	Protocol No.	Title
Ahdoot, Michael	S1806	S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (IRB#384)
Ayodele, Maranatha	BOOST-3	Brain Oxygen Optimization in Severe Traumatic Brain Injury Phase 3 (BOOST-3)
Ayodele, Maranatha	SATURN	STATINS USE IN INRACEREBRAL HEMORRHAGE PATIENTS (SATURN)
Ayoub, Walid	GFT505B-319-1	A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic Acid
Ayoub, Walid	MGL-3196-14	A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
Basho, Reva	MK3475-756	MK3475-756: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2 ) Breast Cancer (IRB#57046)
Burford, Matthew	BCT-003-US	REPEATED ADMINISTRATION OF NUROWN® (AUTOLOGOUS MESENCHYMAL STEM CELLS SECRETING NEUROTROPHIC FACTORS) FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Burford, Matthew	CLN-PXT3003-06	A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
Chen, Peter	014-ACTIV-3-TICO	ACTIV-3: A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19
Chen, Peter	J2X-MC-PYAH	A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy with Monoclonal Antibodies in Participants with Mild to Moderate COVID-19 Illness (BLAZE-4)
Chung, Jeffrey	EP0092	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of Padsevonil As Adjunctive Treatment Of Focal-Onset Seizures In Adult Subjects With Drug-Resistant Epilepsy
Darrah, Justin	A051301	A051301: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype (IRB#557)
Daskivich, Timothy	56021927PCR3011	56021927PCR3011: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy (IRB#31)
Faries, Mark	02-18	02-18: A Phase III, Multi-Centre Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma (IRB#459)
Faries, Mark	IIT2019-17-FARIES-MSLTII	IIT2019-17-FARIES-MSLTII : Multicenter Selective Lymphadenectomy Trial II (MSLT-II): A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node (IRB#241)
Figlin, Robert	MK6482-011	MK6482-011:An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy (IRB#1104)
Figlin, Robert	MK6482-012	MK6482-012: An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (IRB#1396)
Fleshner, Phillip	STUDY-D-PLEX-311	PolyPid Ltd. / Phase III, Prospective, Multinational, Multi center,Randomized, Controlled, Two-arm, Double Blind Study to assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), compared to a SoC treated control arm, in prevention of post abdominal surgery incisional infection
Friedman, Oren	ACTIV-4-ACUTE	A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19
Giuliano, Armando	AFT-25	AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial (IRB#48166)
Gong, Jun	849-010	849-010: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (IRB#1551)
Gong, Jun	A021703	A021703: Randomized, Double-Blind, Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS) (IRB#694)
Gong, Jun	EA2176	EA2176: A randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer (IRB#1317)
Gupta, Amit	IIT-BCGPREDICTIONASSAY	BCGPREDICTIONASSAY: BCG Prediction Assay: A NOVEL MULTIPLEX IMMUNOASSAY FOR PREDICTING INTRAVESICAL BCG RESPONSE IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (IRB#914)
Gupta, Amit	IIT2019-04-ROSSER-GH	IIT2019-04-ROSSER-GH: A Novel Multiplex ELISA Assay for Evaluating Patient with gross hematuria for bladder cancer (IRB#57056)
Gupta, Amit	IIT2019-05-ROSSER-MICROH	IIT2019-05-ROSSER-MICROH: A Novel Multiplex ELISA Assay for Evaluating Patients with Microscopic Hematuria for Bladder Cancer (IRB#57068)
Gutierrez, Rodolfo	R2810-ONC-1788	R2810-ONC-1788: A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy In Patients with High Risk Cutaneous Squamous Cell Carcinoma (IRB#57958)
Hage, Antoine	RIN-PH-304	A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Hu, Jethro	EF-32	EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study of Optune® (TTFields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (IRB#0973)
Huang, Edmund	VKTX01	A PIVOTAL PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CLAZAKIZUMAB FOR THE TREATMENT OF CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT RECIPIENTS
Kamil, Elaine	021FSGS16010	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Kim, Hyung	S1931	S1931: Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial) (IRB# 1168)
Labadzhyan, Artak	CRN00808-09	A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands
Labadzhyan, Artak	TCH-306	foresiGHt: A multicenter, randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily somatropin product in adults with growth hormone deficiency
Lewis, Richard	CY5031	A PHASE 3, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RELDESEMTIV IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Majlessipour, Fataneh	AALL1731	AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) (IRB#0140)
Majlessipour, Fataneh	AALL1732	AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (IRB#654)
Majlessipour, Fataneh	AAML1831	AAML1831: A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations (IRB#952)
Majlessipour, Fataneh	AGCT1531	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors (IRB#436)
Majlessipour, Fataneh	ANBL1232	Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma (IRB#40692)
Majlessipour, Fataneh	ANBL1531	ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) (IRB#1081)
Makkar, Rajendra	2020-05	Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device
Makkar, Rajendra	ABT-CIP-10304	Percutaneous MitraClipTM Device or Surgical Mitral Valve REpair in PAtients with PrImaRy Mitral Regurgitation who are Candidates for Surgery (REPAIR MR)
Natale, Ronald	D910LC00001	D910LC00001: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1) (IRB#0960)
Noureddin, Mazen	ARAMCHOL-018	A Phase 3/4, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH)
Noureddin, Mazen	MGL-3196-11	A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
Osipov, Arsen	A021806	A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer (IRB#1039)
Paquette, Ronald	S1803	S1803: Phase III Study Of Daratumumab/ /rHuPH20 (NSC- 810307) + Lenalidomide Or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (Mm) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY) (IRB#755)
Patel, Jignesh	AG10-304	An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Patel, Jignesh	D1690C00078	Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
Patel, Jignesh	ION-682884-CS2	A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Posadas, Edwin	PBP-301	PBP-301: SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment (IRB#1437)
Rader, Florian	CR0002	A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects with Hypertension
Rader, Florian	CY6022	AN OPEN-LABEL STUDY OF CK3773274 FOR PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM) AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION
Rader, Florian	MYK-461-017	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy
Reckamp, Karen	EA5163	EA5163: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis (IRB#1325)
Rimel, Bobbie Jo	AVB500-OC-004	AVB500-OC-004: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer (GOG-3059) (IRB#1417)
Rimel, Bobbie Jo	NRG-GY018	NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer (IRB#474)
Rokhsar, Sepehr	S1826	S1826 :A Phase III Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/=12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (IRB#1880)
Rudnick, Jeremy	DB102-01	DB102-01: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1 (IRB#1159)
Sundaram, Vinay	IG1407	Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality
Tagliati, Michele	CVL-751-PD-001-TEMPO-1	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON S DISEASE (TEMPO-1 TRIAL)
Tagliati, Michele	CVL-751-PD-003	A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAVAPADON AS ADJUNCTIVE THERAPY FOR PARKINSON?S DISEASE IN LEVODOPA-TREATED ADULTS WITH MOTOR FLUCTUATIONS (TEMPO-3 TRIAL)
Tagliati, Michele	CVL-751-PD-004	58-Week Open-label Trial of Tavapadon in Parkinson s Disease (TEMPO-4 Trial)
Tagliati, Michele	M15-736-ABBV-951	Advanced Parkinson's Disease: Double-Blind, Double-Dummy, Active-Controlled, Efficacy and Safety Study of ABBV-951 Versus Oral Carbidopa/Levodopa
Tagliati, Michele	ND0612-317	A multicenter, randomized, active-controlled, double-blind, doubledummy,parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson's disease experiencing motor fluctuations (BouNDless)
Torbati, Sam	C3PO	Clinical Trial of COVID-19 Convalescent Plasma in Outpatients: A multicenter, two arm, randomized, single-blind clinical trial to determine if receiving one dose of convalescent plasma (CP) for mild COVID-19 illness prevents illness progression
Zabner, Rachel	AIC316-03-II-01-PHASE3	A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects (PRIOH-1)
Zaghiyan, Karen	SAFE-2	SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study A Study to Evaluate the Safety and Effectiveness of the Colovac Colorectal Anastomosis Protection Device.
Zumsteg, Zachary	NRG-GU009	NRG-GU009: PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT) Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation (IRB#1334)